The firm will launch a Phase I trial in healthy volunteers in the Netherlands to establish safety and proof-of-target engagement.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback